Phospho-TP53 (S15) Antibody

Code CSB-PA000595
Size US$167
Image
  • Western Blot analysis of HT29 cells using Phospho-p53 (S15) Polyclonal Antibody
  • Western Blot analysis of 293T cells using Phospho-p53 (S15) Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P04637
Target Names TP53
Alternative Names Antigen NY-CO-13 antibody; BCC7 antibody; Cellular tumor antigen p53 antibody; FLJ92943 antibody; LFS1 antibody; Mutant tumor protein 53 antibody; p53 antibody; p53 tumor suppressor antibody; P53_HUMAN antibody; Phosphoprotein p53 antibody; Tp53 antibody; Transformation related protein 53 antibody; TRP53 antibody; tumor antigen p55 antibody; Tumor protein 53 antibody; Tumor protein p53 antibody; Tumor suppressor p53 antibody
Raised in Rabbit
Species Reactivity Human,Rat
Immunogen Synthesized peptide derived from Human p53 around the phosphorylation site of S15.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications WB, IHC, IP, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IP 2-5ug
IF 1:200-1:1000
ELISA 1:10000
Protocols Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2
Gene References into Functions
  1. Study summarizes the different functions of p53 in adipocyte development and in adipose tissue homeostasis. Furthermore, It explores the manipulation of p53 levels in adipose tissue depots and the impact on systemic energy metabolism in the context of insulin resistance and obesity. [review] PMID: 30181511
  2. a USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells PMID: 29593334
  3. Results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. PMID: 29471073
  4. Studied association of tumor protein p53 and drug metabolizing enzyme polymorphisms with clinical outcome in patients with advanced nonsmall cell lung cancer. PMID: 28425245
  5. POH1 knockdown induced cell apoptosis through increased expression of p53 and Bim. PMID: 29573636
  6. a heretofore unappreciated effect of chronic high fat diet on beta-cells, wherein continued DNA damage owing to persistent oxidative stress results in p53 activation and a resultant inhibition of mRNA translation. PMID: 28630491
  7. diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53. PMID: 28484276
  8. that proliferation potential-related protein promotes esophageal cancer cell proliferation and migration, and suppresses apoptosis by mediating the expression of p53 and IL-17 PMID: 30223275
  9. Infection of HIV-1 and subsequent HIV-1 reverse transcription are inhibited in HCT116 p53(+/+) cells in comparison to HCT116 p53(-/-) cells. Tumor suppressor gene p53 expression is upregulated in non-cycling cells. The restrictions of HIV by p53 is associated with the suppression of ribonucleotide reductase R2 subunit expression and phosphorylation of SAMHD1 protein. PMID: 29587790
  10. It has been shown that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type T-cell lymphomas. PMID: 29789628
  11. A significant increase in the expression of p53 and Bax was observed in cells treated with alpha-spinasterol, while cdk4/6 were significantly down-regulated upon exposure to alpha-spinasterol. PMID: 29143969
  12. There was a significant correlation between telomere dysfunction indices, p53, oxidative stress indices, and malignant stages of GI cancer patients PMID: 29730783
  13. PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma. PMID: 29644528
  14. these data indicate that activation of autophagy reduces expression of STMN1 and p53, and the migration and invasion of cancer cells contributes to the anti-cancer effects of the Halofuginone. These findings may provide new insight into breast cancer prevention and therapy. PMID: 29231257
  15. miR-150 suppresses cigarette smoke-induced lung inflammation and airway epithelial cell apoptosis, which is causally linked to repression of p53 expression and NF-kappaB activity. PMID: 29205062
  16. tumors harboring TP53 mutations, which can impair epithelial function, have a unique bacterial consortium that is higher in relative abundance in smoking-associated tumors. PMID: 30143034
  17. crosstalk among p53, lipid metabolism, insulin resistance, inflammation and oxidative stress has roles in Non-alcoholic fatty liver disease [review] PMID: 30473026
  18. Ubiquitin-conjugating enzyme E2S (UBE2S) enhanced the ubiquitination of p53 protein to facilitate its degradation in hepatocellular carcinoma (HCC) cells. PMID: 29928880
  19. p53 knockout compensates osteopenia in murine Mysm1 deficiency. PMID: 29203593
  20. SIRT1 had a pivotally protective role in the regulation of ADSCs aging and apoptosis induced by H2O2 PMID: 29803744
  21. 133p53 promotes tumour invasion via IL-6 by activation of the JAK-STAT and RhoA-ROCK pathways. PMID: 29343721
  22. mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy. PMID: 30126368
  23. PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III colorectal cancer PMID: 28782638
  24. This study of patients with ccRCC, pooled analysis and multivariable modeling demonstrated that three recurrently mutated genes, BAP1, SETD2, and TP53, have statistically significant associations with poor clinical outcomes. Important clinical confounders, mutations of TP53 and SETD2 were associated with decreased CSS and RFS, respectively. PMID: 28753773
  25. Study revealed that the Wnt/beta-catenin signaling pathway and its major downstream target, c-Myc increased the miR552 levels and miR552 directly targets p53 tumor suppressor. miR552 may serve as an important link between functional loss of APC, leading to abnormal Wnt signals, and the absence of p53 protein in colorectal cancer. PMID: 30066856
  26. High levels of glucose leads to endothelial dysfunction via TAF1-mediated p53 Thr55 phosphorylation and subsequent GPX1 inactivation. PMID: 28673515
  27. Although tumor protein p53 (p53) does not directly control the luminal fate, its loss facilitates acquisition of mammary stem cell (MaSC)-like properties by luminal cells and predisposes them to development of mammary tumors with loss of luminal identity. PMID: 28194015
  28. Fifty-two percent of patients diagnosed with glioma/glioblastoma with a positive TP53 mutation. PMID: 29454261
  29. the expression of Ser216pCdc25C was also increased in the combined group, indicating that irinotecan likely radiosensitized the p53-mutant HT29 and SW620 cells through the ATM/Chk/Cdc25C/Cdc2 pathway. PMID: 30085332
  30. In the former, p53 binds to the CDH1 (encoding E-cadherin) locus to antagonize EZH2-mediated H3K27 trimethylation (H3K27me3) to maintain high levels of acetylation of H3K27 (H3K27ac). PMID: 29371630
  31. Among the hits, miR-596 was identified as a regulator of p53. The overexpression of miR-596 significantly increased p53 at the protein level, thereby inducing apoptosis. PMID: 28732184
  32. Apoptosis pathways are impaired in fibroblasts from patients with SSc, leading to chronic fibrosis. Nonetheless, PUMA/p53 pathway may not be involved in dysfunction of apoptosis mechanisms in fibroblasts of patients with SSc. PMID: 28905491
  33. Low TP53 expression is associated with drug resistance in colorectal cancer. PMID: 30106452
  34. The activation of p38 in response to low doses of ultraviolet radiation was postulated to be protective for p53-inactive cells. Therefore, MCPIP1 may favor the survival of p53-defective HaCaT cells by sustaining the activation of p38. PMID: 29103983
  35. TP53 missense mutations are associated with castration-resistant prostate cancer. PMID: 29302046
  36. P53 degradation is mediated by COP1 in the breast cancer. PMID: 29516369
  37. Combined inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 efficiently induces brain tumours with hallmark characteristics of human glioblastoma. PMID: 28094268
  38. A direct link between Y14 and p53 expression and suggests a function for Y14 in DNA damage signaling. PMID: 28361991
  39. TP53 Mutation is associated with Mouth Neoplasms. PMID: 30049200
  40. Cryo-Electron Microscopy studies on p53-bound RNA Polymerase II (Pol II) reveal that p53 structurally regulates Pol II to affect its DNA binding and elongation, providing new insights into p53-mediated transcriptional regulation. PMID: 28795863
  41. Increased nuclear p53 phosphorylation and PGC-1alpha protein content immediately following SIE but not CE suggests these may represent important early molecular events in the exercise-induced response to exercise PMID: 28281651
  42. E6/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis PMID: 28303973
  43. accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2. PMID: 28348409
  44. Consistently, forced expression of p53 significantly stimulated ACER2 transcription. Notably, p53-mediated autophagy and apoptosis were markedly enhanced by ACER2. Depletion of the essential autophagy gene ATG5 revealed that ACER2-induced autophagy facilitates its effect on apoptosis. PMID: 28294157
  45. results indicate that LGASC of the breast is a low-grade triple-negative breast cancer that harbours a basal-like phenotype with no androgen receptor expression, and shows a high rate of PIK3CA mutations but no TP53 mutations PMID: 29537649
  46. this study shows an inhibitory effect of wild-type P53 gene transfer on graft coronary artery disease in rat model PMID: 29425775
  47. Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to breast cancer in Moroccan population PMID: 29949804
  48. higher level of the p53 isoform, p53beta, predict better prognosis in patients with renal cell carcinoma through enhancing apoptosis in tumors. PMID: 29346503
  49. TP53 mutations are associated with colorectal liver metastases. PMID: 29937183
  50. High expression of TP53 is associated with oral epithelial dysplasia and oral squamous cell carcinoma. PMID: 29893337
  51. High rate of TP53 R249S mutation has been found in cell-free DNA of middle African patients with hepatocellular carcinoma. PMID: 29749584
  52. Low TP53 expression is associated with chemoresistance in ovarian cancer. PMID: 29956807
  53. The TP53 codon 72 polymorphism had a significant association with the FSH/LH ratio (group I: FSH/LH <2.3 and group II: FSH/LH >/=2.3) (C/C vs. G/G: odds ratio [OR] = 1.69, 95% confidence interval [CI]: 1.07-2.65, p = 0.02; G/C vs. G/G: OR = 1.86, 95% CI: 1.25-2.77, p = 0.002). PMID: 29957069
  54. Differentiation-dependent downregulation of p53 is a prerequisite for activating autophagy in the syncytiotrophoblast. PMID: 29080089
  55. Significant increase in frequencies ofTP53 (rs1042522 G/C), BRCA1 (rs71361504 -/GTT, rs3092986T/C) genotypes and alleles in polycystic ovary patients compared to controls. PMID: 29860059
  56. p53 expression showed a statistically significant impact on renal cell carcinoma disease progression , albeit not on cancer-specific mortality. PMID: 29221641
  57. Deletion of NF1 leads to mutant oligodendrocyte precursor cell (OPC) expansion through increased proliferation and decreased differentiation, the deletion of p53 impairs OPC senescence. Signaling analysis showed that, while PI3K and MEK pathways go through stepwise over-activation, mTOR signaling remains at the basal level in pre-transforming mutant OPCs but is abruptly up-regulated in tumor OPCs. PMID: 29392777
  58. Study discovered that a p53-dependent tumor-suppressor (TS) network triggered by nucleolar stress is tuned by miR-101. Activation of this network, the p53-miR-101 circuit, enables induction of apoptosis in p53 WT cancer cells by G2 phase-specific positive-feedback regulation of p53 mediated by direct repression of EG5. PMID: 30049386
  59. In silico molecular docking and dynamics studies with MDM2-p53 protein revealed that HTMF was more potent compound that could inhibit the binding of MDM2 with p53 and, therefore, could trigger apoptosis in cancer cell. PMID: 29734849
  60. Expression of Ki-67 was lower and expression of p53 was higher in primary tumors than in ascitic cells PMID: 29801775
  61. This review outlines the roles of important E3(Ub)-ligases and their splice variants in maintaining cellular p53 protein homeostasis. [review] PMID: 30199707
  62. This result suggests that p53 has an important role in hemangioma endothelial cell (HemEC) apoptosis. The results of the present study additionally suggest that the propranololinduced HemEC apoptosis pathway is a mitochondrial apoptosis pathway and is regulated by p53BAX signaling. PMID: 29767244
  63. Our findings suggested that RBM38 may be a core contributor in stabilizing the p53-mdm2 loop function to prevent hepatocellular carcinoma (HCC) and a potential novel target to provide a therapeutic strategy for HCC by inhibiting mdm2 and rescuing p53 from inactivation. PMID: 30176896
  64. If, as expected, the consequences of the deregulation of the CDKN1C-E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential therapeutic strategies in human Precursor T-cell lymphoblastic lymphomas PMID: 29661169
  65. Study reports that p53 is a transcriptional regulator of RCC2 that acts through its binding to a palindromic motif in the RCC2 promoter. p53 and RCC2 signaling is important for regulation of cell migration and suppression of metastasis. PMID: 28869598
  66. Data found that trp53 was highly expressed in human bladder cancer tissues. Further investigation revealed that TPX2 activated the synthesis of p53 which wild-type form up-regulated GLIPR1 but not the mutated form. PMID: 28799673
  67. Identifying a TP53 mutation in a gene panel test is a challenging result for the patient and clinician due to the high risk of second primaries and the lack of consensus about surveillance PMID: 29039119
  68. p53 expression was reduced by activation of nuclear factor-kappaB that depended on elevated levels of free calcium in HCT116/rho cells. PMID: 29580374
  69. The total mutation frequency of p53 gene in 150 patients with familial breast cancer and early-onset breast cancer from partpopulation of southern China is higher than the frequency previously reported. The pathogenicity of the novel mutations (insert mutation) 869_888ins20 will be confirmed by function analysis in the future study. The deletion mutation 643_660del18 enriches the p53 gene mutation database among Chinese PMID: 28626092
  70. the present study demonstrated that the function of KPNA2 in the process of autophagy may be p53dependent, and by regulating the translocation of p53, KPNA2 can support autophagy to promote the chemoresistance and metastasis of oral squamous cell carcinoma (OSCC) cells. PMID: 29781035
  71. Meta-analysis revealed that TP53 alterations serve as a clinical and prognostic factor for glioma patients carrying H3K27M mutations and are associated with the status of H3.3 mutations and a higher WHO grade. Data highlight the role of TP53 alterations in patient survival and suggest that, with successful TP53 reactivation, we may be able to increase the survival of glioma patients harboring mutant K27M and TP53. PMID: 29651718
  72. Results found abnormal expression of TP53 in 87.6% of ovarian high-grade serous carcinoma (HGSC) and 13.3% of low-grade serous carcinoma (LGSC) samples. It can be use along with AGR3 for differential diagnosis of HGSC and LGSC. PMID: 29620196
  73. The mRNA expression of FAS was lower in patients with TP53 mutation than TP53 wild-type. Our findings suggest that TP53 mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade. PMID: 29793878
  74. The relation between Ser15 or Ser20 and tumor cell viability might reflect their role in tumor sensitivity on chemotherapy in dependent p53 protein status. PMID: 29684847
  75. findings uncover a new function of p53 in the regulation of Akt signaling and reveal how p53, ASS1, and Akt are interrelated to each other. PMID: 28560349
  76. In the present study, immunostaining p53 showed 90% sensitivity, 89.3% specificity, positive predictive value of 52.9%, and negative predictive value of 98.5%. The technical simplicity, easy availability, and comparatively lower cost enhance the role of p53 as a biomarker in risk stratification for patients with Barrett esophagus. PMID: 29676351
  77. Data show no patient positive for KRAS mutation and/or p53 mutation was found to have malignant transformation, suggesting detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas. PMID: 29303908
  78. Study identified p53 as a key factor for UVB-induced melanocyte senescence and senescence-associated hyperpigmentation through its increased expression and sustained high levels following UVB exposure. PMID: 29525471
  79. These findings demonstrate the critical regulation of TIP60/p53 pathway in apoptosis upon metabolic stress and provide a novel insight into the down-regulation of TIP60 in tumor cells. PMID: 29174981
  80. PEPD directly binds to p53 in the nucleus and cytoplasm and suppresses both transcription-dependent and transcription-independent activities of p53, which does not require PEPD enzymatic activity. PMID: 29233996
  81. These results suggest that p53 codon 72 polymorphism could not be assessed as a risk factor marker for predisposition to breast cancer in Rwanda. PMID: 29131100
  82. study assessed the frequency of the TP53 Arg72Pro polymorphism in healthy volunteers and patients with acute myeloid leukemia (AML) and evaluated its clinical impact on outcomes of non-selected patients with AML PMID: 27846614
  83. Our results suggest that CSCs in the ER(+) cells escape the effect of DOX treatment by the elevation of p53 expression PMID: 29779937
  84. these findings indicated that miR31a5p is involved in hypertension via the accelerated proliferation of arterial smooth muscle cells and inhibition of apoptosis through targeting TP53. PMID: 29620173
  85. Histopathological features, i.e. presence of low-grade areas, may play a role in classifying Glioblastoma (GB) into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary. PMID: 29664032
  86. tumor suppressor p53 functions as an essential antiviral molecule against Japanese encephalitis virus PMID: 27956051
  87. DPYSL4 plays a key role in the tumor-suppressor function of p53 by regulating oxidative phosphorylation and the cellular energy supply via its association with mitochondrial supercomplexes, possibly linking to the pathophysiology of both cancer and obesity. PMID: 30061407
  88. Data suggest a close association between the nonfunctionality of ATM/p53 pathway and accumulation of p27Kip1 in chronic lymphocytic leukemia (CLL) cells in response to DNA damage. PMID: 27268868
  89. Novel TP53 variants were identified in cases of high-grade serous ovarian cancer. PMID: 29783665
  90. Glutaredoxin-1 silencing induces cell senescence via p53/p21/p16 signaling axis. PMID: 29356545
  91. Results showed that the crystal structure of mutant p53R280K DNA binding domain (DBD) revealed that, as in wt p53, there is a correct folding of mutant p53R280K DBD, without any crevice and with zinc(II) ion coordination. Most importantly, it indicated that the loss of function is likely related to the inability of the residue K280 to establish two hydrogen bonds with DNA. PMID: 29652801
  92. Double mutation of PIK3CA and TP53 is an independent predictive factor for overall survival in stage II/III colorectal cancer patients receiving 5-FU-based chemotherapy. PMID: 29434452
  93. In southern Brazil, pediatric adrenocortical tumor is a sentinel cancer for detecting families with germline p.R337H mutation in TP53 gene. PMID: 28864397
  94. p16, p21, and p53 proteins play an important role in the deregulation of the cell cycle and participate in the development of pancreatic intraepithelial neoplasia. PMID: 29388054
  95. PHLDB3 promotes tumour growth by inactivating p53 in a negative feedback fashion. PMID: 28008906
  96. DNA damage induces ISG15 conjugation to p53 and this modification markedly enhances the binding of p53 to the promoters of its target genes as well as of its own gene by promoting phosphorylation and acetylation. PMID: 27545325
  97. Nucleoplasmic translocation of NPM1 is a prerequisite for stress-induced activation of p53. PMID: 27886181
  98. The p53 promoter polymorphism is not associated with the susceptibility of uterine leiomyomas in Iranian women. PMID: 30074324
  99. Authors conclude that quantitative measurements of intratumor heterogeneity by multiplex FISH, detection of MYC amplification and TP53 mutation could augment prognostication in breast cancer patients. PMID: 29181861
  100. Y chromosome long arm genes regulation of testicular apoptosis seems to be restricted to the initial wave of spermatogenesis and is not evident in adult gonads. p53 does participate in spontaneous apoptosis in mature testes. PMID: 28763629

Show More

Hide All

Involvement in disease Esophageal cancer (ESCR); Li-Fraumeni syndrome (LFS); Squamous cell carcinoma of the head and neck (HNSCC); Lung cancer (LNCR); Papilloma of choroid plexus (CPP); Adrenocortical carcinoma (ADCC); Basal cell carcinoma 7 (BCC7)
Subcellular Location Cytoplasm, Nucleus, Nucleus, PML body, Endoplasmic reticulum, Mitochondrion matrix, Note=Interaction with BANP promotes nuclear localization, Recruited into PML bodies together with CHEK2, Translocates to mitochondria upon oxidative stress, Translocates to mitochondria in response to mitomycin C treatment (PubMed:27323408), SUBCELLULAR LOCATION: Isoform 1: Nucleus, Cytoplasm, Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4, SUBCELLULAR LOCATION: Isoform 2: Nucleus, Cytoplasm, Note=Localized mainly in the nucleus with minor staining in the cytoplasm, SUBCELLULAR LOCATION: Isoform 3: Nucleus, Cytoplasm, Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells, SUBCELLULAR LOCATION: Isoform 4: Nucleus, Cytoplasm, Note=Predominantly nuclear but translocates to the cytoplasm following cell stress, SUBCELLULAR LOCATION: Isoform 7: Nucleus, Cytoplasm, Note=Localized mainly in the nucleus with minor staining in the cytoplasm, SUBCELLULAR LOCATION: Isoform 8: Nucleus, Cytoplasm
Protein Families P53 family
Tissue Specificity Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3
Database Links

HGNC: 11998

OMIM: 133239

KEGG: hsa:7157

STRING: 9606.ENSP00000269305

UniGene: Hs.437460

Most popular with customers

  Tel: 301-363-4651
  Email: support@cusabio.com
  Distributors Worldwide

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1